Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment

J Fung, CL Lai, J Young, DKH Wong… - Official journal of the …, 2011 - journals.lww.com
OBJECTIVES: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients
receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response …

[HTML][HTML] Clinical utility of hepatitis B surface antigen kinetics in treatment-naive chronic hepatitis B patients during long-term entecavir therapy

TC Lin, YC Chiu, HC Chiu, WC Liu… - World journal of …, 2018 - ncbi.nlm.nih.gov
AIM To investigate the utility of hepatitis B surface antigen (HBsAg) kinetics in chronic
hepatitis B patients during long-term entecavir treatment. METHODS This retrospective study …

Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen-positive patients receiving entecavir

YK Jung, JH Kim, YS Lee, HJ Lee, E Yoon… - Journal of clinical …, 2010 - journals.lww.com
Results Twenty-eight patients were treated for a median period of 21 months (range: 18 to
24 mo). Serum HBsAg level showed a mean of 4.0, 3.7, and 3.6 log 10 IU/mL at …

Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection

CH Chen, CH Hung, TH Hu, JH Wang, SN Lu… - Clinical …, 2015 - Elsevier
Background & Aims We investigated the rate of relapse of hepatitis B virus (HBV) infection
after entecavir therapy for chronic hepatitis B and the association between level of hepatitis …

Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B

MH Lee, DM Lee, SS Kim, JY Cheong… - Journal of medical …, 2011 - Wiley Online Library
Recent studies have suggested that quantifying the serum HBsAg levels can predict the
response to pegylated interferon. We aimed to determine the change in serum HBsAg levels …

[HTML][HTML] Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B

HA Lee, YS Seo, SW Park, SJ Park… - Clinical and …, 2016 - ncbi.nlm.nih.gov
Methods This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years,
mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; …

Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir

CC Wang, KC Tseng, CY Peng… - Journal of …, 2013 - Wiley Online Library
Abstract Background and Aim Although entecavir has been shown to have good efficacy
and low resistance for the treatment of chronic hepatitis B (CHB), factors associated with a …

[HTML][HTML] Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B

CY Peng, HC Lai, WP Su, CH Lin, PH Chuang… - Scientific reports, 2017 - nature.com
Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and
association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving …

Changes of HBsAg and HBV DNA levels in C hinese chronic hepatitis B patients after 5 years of entecavir treatment

WK Seto, YF Lam, J Fung, DKH Wong… - Journal of …, 2014 - Wiley Online Library
Abstract Background and Aim Hepatitis B surface antigen (HBsAg) kinetics during long‐term
entecavir therapy has not been well investigated. Methods We described the cumulative …

Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy

CH Chen, TH Hu, JH Wang, HC Lai, CH Hung… - Hepatology …, 2020 - Springer
Background/purpose The study compared the hepatitis B surface antigen (HBsAg) changes
between hepatitis B e antigen (HBeAg)-negative non-cirrhotic chronic hepatitis B patients …